Presentation is loading. Please wait.

Presentation is loading. Please wait.

Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.

Published byAshlie Logan Modified over 9 years ago

Similar presentations

Presentation on theme: "Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert."— Presentation transcript:

1 Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert G Tieleman, PhD, MD Robert G Tieleman, PhD, MD Department of Cardiology Cardiovascular Research Institute Maastricht University Medical Centre, The Netherlands Martini Hospital Groningen, The Netherlands

2 Euro Heart Survey Antithrombotics according to CHADS2 score  Poor adherence to guidelines on management of AF  Non-adherence to guidelines increased morbidity / mortality Nieuwlaat et al. EHJ 2005, 2006

3 Multivariate analysis antithrombotic guideline deviance Nieuwlaat et al. Am Heart J 2007

4 The AF-Clinic An integrated chronic care program for patients with atrial fibrillation  Substitution of care by specialized nurses  Management of AF according to guidelines  Dedicated knowledge software  Supervision by cardiologists

5

6 Nurse-led, guideline based, software-supported AF-Clinic, supervised by cardiologists improves clinical outcome in patients with atrial fibrillation in comparison to usual care Hypothesis

7 Methods  PROBE: Prospective, Randomized, Open label, Blinded Endpoint trial, comparing the AF-Clinic to usual care  Randomization of 712 pts with newly diagnosed AF into Nurse-led Care group or Usual Care group  Inclusion criteria  Age ≥ 18 years  AF documented on ECG  Exclusion criteria  Unsatisfactorily treated co-morbidity (hypertension, heart failure, …)  Follow-up at least 1 year

8 Primary endpoint (composite)  Cardiovascular mortality  Cardiovascular hospitalization for  Heart failure  Stroke  Acute myocardial infarction  Systemic embolism  Bleeding  Arrhythmic events  Atrial Fibrillation  Syncope  Sustained ventricular tachycardia  Cardiac arrest  Life-threatening effects of drugs

9 Baseline characteristics CharacteristicsNurse-led Care (N = 356)Usual Care (N = 356) Age - yr66 ± 1367 ± 12 Male sex - no (%)197 (55.3)221 (62.1) Type of AF - no (%) Paroxysmal190 (53.4)203 (57.0) Persistent 68 (19.1) 44 (12.4) Permanent 75 (21.1) 84 (23.6) Symptomatic AF - no (%)294 (82.6)296 (83.1) History of underlying disease Hypertension187 (52.5)193 (54.2) Diabetes mellitus 50 (14.0) 46 (12.9) Previous stroke / TIA 44 (12.4) 45 (12.6) Coronary artery disease 33 (9.3) 38 (10.7) Myocardial infarction 19 (5.3)22 (6.2) Congestive heart failure 25 (7.0) Peripheral vascular disease 13 (3.7)20 (5.6) Hyperthyroidism 12 (3.4) Mitral or aortic valve disease 12 (3.4)21 (5.9) No underlying heart disease 6 (1.7) 7 (2.0)

10 Baseline characteristics CharacteristicsNurse-led Care (N = 356)Usual Care (N = 356) CHADS2 score - no (%) 0107 (30.0) 95 (26.7) 1122 (34.3)135 (37.9) >1127 (35.7)126 (35.4) Threatment - no (%) Beta-blocker164 (46.1)187 (52.5) Digitalis 59 (16.6) 43 (12.1) Verapamil 44 (12.4) 18 (5.1) Vaughan-Williams class I & III105 (29.1) 88 (24.7) Vitamin K antagonist218 (61.2)188 (52.8) Aspirin118 (33.1)108 (30.3) Echocardiographic findings Size of left atrium, long axis - mm42 ± 643 ± 8 LV end-diastolic size - mm49 ± 6 LV end-systolic size - mm34 ± 6 LV ejection fraction - %57 ± 1056 ± 12

11 Results After a mean follow-up of 22 months  Composite end point - 51 patients (14.3%) Nurse-led Care - 74 patients (20.8%) Usual Care (HR 0.65, 95% CI 0.45-0.93)

12 Results: composite endpoint

13 Results  Cardiovascular hospitalization - 48 patients (13.5%) Nurse-led Care - 68 patients (19.1%) Usual Care (HR 0.66, 95% CI 0.46-0.96)

14 Causes of cardiovascular hospitalization

15 Results  Cardiovascular death - 4 patients (1.1%) Nurse-led Care - 14 patients (3.9%) Usual Care (HR 0.28, 95% CI 0.09-0.85)

16 Causes of cardiovascular death

17 Results: guideline adherence  Echocardiogram performed  Laboratory assessment of Thyroid Stimulating Hormone  Application of appropriate anti- thrombotic treatment  Appropriate prescription of Vaughan-Williams class I or III  Avoiding rhythm control strategy in asymptomatic patients  Avoiding rhythm control drugs in patients with permanent AF

18 Results: guideline adherence  Echocardiogram performed  Laboratory assessment of Thyroid Stimulating Hormone  Application of appropriate anti- thrombotic treatment  Appropriate prescription of Vaughan-Williams class I or III  Avoiding rhythm control strategy in asymptomatic patients  Avoiding rhythm control drugs in patients with permanent AF

19 Conclusion Management of atrial fibrillation patients in a specialized AF-Clinic improves outcome compared to usual care.

20 Members of the study group Writing Committee HJGM Crijns JML Hendriks RG Tieleman HJM Vrijhoef R de Wit MH Prins R Pisters LAFG Pison Y Blaauw Steering Committee HJGM Crijns RG Tieleman R de Wit HJM Vrijhoef Adjudication Committee C Franke H ten Cate GVA van Ommen RJMW Rennenberg

21 Back-up slides

22 Discussion Difficult to pinpoint nurses or guidelines or dedicated software as the sole reason for results Improved guideline adherence and outcomes due to an integrated approach: a combination of ingredients

23 Results: multivariate analyses

Download ppt "Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert."

Similar presentations

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.

RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.
New Atrial Fibrillation/Flutter Pathway and GRASP Tool

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Study by: Granger et al. NEJM, September 2011,Vol. 365. No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.

Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ 2008-1 Thrombus Aspiration during Percutaneous coronary intervention in Acute.

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.

Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Dr Avinash Haridas Pillai

Dr Avinash Haridas Pillai
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Www.isdscotland.org SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.

SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.

Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.

Similar presentations

Ads by Google